Corticosteroids for Bacterial Keratitis
Archives of Ophthalmology · 01.02.2012 · 130 (2) · 143
DOI: 10.1001/archophthalmol.2011.315 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Archives of Ophthalmology, erschienen am 01.02.2012. Verfasst von Muthiah Srinivasan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Cornea and External Diseases, Aravind Eye Care System, Madurai, India. Die Arbeit wurde bisher 194-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
OBJECTIVE: To determine whether there is a benefit in clinical outcomes with the use of topical corticosteroids as adjunctive therapy in the treatment of bacterial corneal ulcers. METHODS: Randomized, placebo-controlled, double-masked, multicenter clinical trial comparing prednisolone sodium phosphate, 1.0%, to placebo as adjunctive therapy for the treatment of bacterial corneal ulcers. Eligible patients had a culture-positive bacterial corneal ulcer and received topical moxifloxacin for at least 48 hours before randomization. MAIN OUTCOME MEASURES: The primary outcome was best spectacle-corrected visual acuity (BSCVA) at 3 months from enrollment. Secondary outcomes included infiltrate/scar size, reepithelialization, and corneal perforation. RESULTS: Between September 1, 2006, and February 22, 2010, 1769 patients were screened for the trial and 500 patients were enrolled. No significant difference was observed in the 3-month BSCVA (-0.009 logarithm of the minimum angle of resolution [logMAR]; 95% CI, -0.085 to 0.068; P = .82), infiltrate/scar size (P = .40), time to reepithelialization (P = .44), or corneal perforation (P > .99). A significant effect of corticosteroids was observed in subgroups of baseline BSCVA (P = .03) and ulcer location (P = .04). At 3 months, patients with vision of counting fingers or worse at baseline had 0.17 logMAR better visual acuity with corticosteroids (95% CI, -0.31 to -0.02; P = .03) compared with placebo, and patients with ulcers that were completely central at baseline had 0.20 logMAR better visual acuity with corticosteroids (-0.37 to -0.04; P = .02). CONCLUSIONS: We found no overall difference in 3-month BSCVA and no safety concerns with adjunctive corticosteroid therapy for bacterial corneal ulcers. APPLICATION TO CLINICAL PRACTICE: Adjunctive topical corticosteroid use does not improve 3-month vision in patients with bacterial corneal ulcers. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00324168.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Cornea and External Diseases, Aravind Eye Care System, Madurai, India.
Förderung
- NEI NIH HHS
Zitieren
APA
Srinivasan, M., Mascarenhas, J., Rajaraman, R., Ravindran, M., Lalitha, P., Glidden, D. V., Ray, K. J., Hong, K. C., Oldenburg, C. E., Lee, S. M., Zegans, M. E., McLeod, S. D., Lietman, T. M., Acharya, N. R., & Steroids for Corneal Ulcers Trial Group (2012). Corticosteroids for Bacterial Keratitis. Archives of Ophthalmology, 130(2), 143. https://doi.org/10.1001/archophthalmol.2011.315
Vancouver
Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, et al. Corticosteroids for Bacterial Keratitis. Archives of Ophthalmology. 2012;130(2):143. doi:10.1001/archophthalmol.2011.315
BibTeX
@article{Srinivasan2012,
author = {Srinivasan, Muthiah and Mascarenhas, Jeena and Rajaraman, Revathi and Ravindran, Meenakshi and Lalitha, Prajna and Glidden, David V and Ray, Kathryn J and Hong, Kevin C and Oldenburg, Catherine E and Lee, Salena M and Zegans, Michael E and McLeod, Stephen D and Lietman, Thomas M and Acharya, Nisha R and Steroids for Corneal Ulcers Trial Group, Steroids for Corneal Ulcers Trial Group},
title = {Corticosteroids for Bacterial Keratitis},
journal = {Archives of Ophthalmology},
year = {2012},
volume = {130},
number = {2},
pages = {143},
doi = {10.1001/archophthalmol.2011.315}
}
EUVIMED